Cargando…

Preliminary evidence in treatment of eosinophilic gastroenteritis in children: A case series

BACKGROUND: Eosinophilic gastroenteritis is a rare inflammatory disorder in children. However, there is still no standard guideline in the treatment of pediatric eosinophilic gastroenteritis. AIM: To report our experience with the diagnosis and treatment of children with eosinophilic gastroenteritis...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ying, Sun, Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294883/
https://www.ncbi.nlm.nih.gov/pubmed/35979287
http://dx.doi.org/10.12998/wjcc.v10.i19.6417
_version_ 1784749942770761728
author Chen, Ying
Sun, Mei
author_facet Chen, Ying
Sun, Mei
author_sort Chen, Ying
collection PubMed
description BACKGROUND: Eosinophilic gastroenteritis is a rare inflammatory disorder in children. However, there is still no standard guideline in the treatment of pediatric eosinophilic gastroenteritis. AIM: To report our experience with the diagnosis and treatment of children with eosinophilic gastroenteritis. METHODS: From January 2017 to December 2019, a total of 22 children were diagnosed with eosinophilic gastroenteritis. RESULTS: Endoscopic examination showed eosinophil infiltration in the duodenum [mean number of eosinophils/high-power field (HPF) = 53.1 ± 81.5], stomach (mean number of eosinophils/HPF = 36.8 ± 50.5), and terminal ileum (mean number of eosinophils/HPF = 49.0 ± 24.0). All 18 children with low eosinophil infiltration (< 14%) responded well to the initial drug treatment without relapse, while two of four children with high eosinophil infiltration (> 14%) relapsed after initial methylprednisolone/montelukast treatment. In addition, children with high eosinophil infiltration (> 14%) showed symptomatic relief and histological remission without further relapse after receiving budesonide/methylprednisolone as initial or relapse treatment. CONCLUSION: Methylprednisolone/montelukast is still the best treatment for children with low eosinophil infiltration (< 14%). Budesonide can be considered as the initial or relapse treatment for children with high eosinophil infiltration (> 14%).
format Online
Article
Text
id pubmed-9294883
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-92948832022-08-16 Preliminary evidence in treatment of eosinophilic gastroenteritis in children: A case series Chen, Ying Sun, Mei World J Clin Cases Retrospective Study BACKGROUND: Eosinophilic gastroenteritis is a rare inflammatory disorder in children. However, there is still no standard guideline in the treatment of pediatric eosinophilic gastroenteritis. AIM: To report our experience with the diagnosis and treatment of children with eosinophilic gastroenteritis. METHODS: From January 2017 to December 2019, a total of 22 children were diagnosed with eosinophilic gastroenteritis. RESULTS: Endoscopic examination showed eosinophil infiltration in the duodenum [mean number of eosinophils/high-power field (HPF) = 53.1 ± 81.5], stomach (mean number of eosinophils/HPF = 36.8 ± 50.5), and terminal ileum (mean number of eosinophils/HPF = 49.0 ± 24.0). All 18 children with low eosinophil infiltration (< 14%) responded well to the initial drug treatment without relapse, while two of four children with high eosinophil infiltration (> 14%) relapsed after initial methylprednisolone/montelukast treatment. In addition, children with high eosinophil infiltration (> 14%) showed symptomatic relief and histological remission without further relapse after receiving budesonide/methylprednisolone as initial or relapse treatment. CONCLUSION: Methylprednisolone/montelukast is still the best treatment for children with low eosinophil infiltration (< 14%). Budesonide can be considered as the initial or relapse treatment for children with high eosinophil infiltration (> 14%). Baishideng Publishing Group Inc 2022-07-06 2022-07-06 /pmc/articles/PMC9294883/ /pubmed/35979287 http://dx.doi.org/10.12998/wjcc.v10.i19.6417 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Study
Chen, Ying
Sun, Mei
Preliminary evidence in treatment of eosinophilic gastroenteritis in children: A case series
title Preliminary evidence in treatment of eosinophilic gastroenteritis in children: A case series
title_full Preliminary evidence in treatment of eosinophilic gastroenteritis in children: A case series
title_fullStr Preliminary evidence in treatment of eosinophilic gastroenteritis in children: A case series
title_full_unstemmed Preliminary evidence in treatment of eosinophilic gastroenteritis in children: A case series
title_short Preliminary evidence in treatment of eosinophilic gastroenteritis in children: A case series
title_sort preliminary evidence in treatment of eosinophilic gastroenteritis in children: a case series
topic Retrospective Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294883/
https://www.ncbi.nlm.nih.gov/pubmed/35979287
http://dx.doi.org/10.12998/wjcc.v10.i19.6417
work_keys_str_mv AT chenying preliminaryevidenceintreatmentofeosinophilicgastroenteritisinchildrenacaseseries
AT sunmei preliminaryevidenceintreatmentofeosinophilicgastroenteritisinchildrenacaseseries